Tag: Janssen Biotech

October 29, 2018

TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen

TESARO (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from...
September 27, 2018

Geron Cancels Janssen Collaboration, Share Price Drops

Geron and Johnson & Johnson’s subsidiary, Janssen Biotech, have terminated their partnership on development of a drug for two different...
September 27, 2018

Geron Announces Discontinuation of Imetelstat Collaboration by Janssen

Geron (Nasdaq:GERN) today announced that Janssen Biotech has terminated the 2014 Collaboration and License Agreement (CLA) with the Company. Janssen...
June 8, 2018

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership

Aduro Biotech (NASDAQ:ADRO) announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for...
March 19, 2018

What is Oncology Investing?

What is oncology investing? This sector can be intimidating for investors first getting into the space — here's a brief breakdown...
January 23, 2018

Genmab Announces 2017 Net Sales Figures for DARZALEX®

Genmab (Nasdaq:GEN) announced that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million...
April 10, 2017

Geron Receives Review Data For Two Imetelstat Trials

Geron Corporation announced the completion of second internal data reviews for the Imetelstat trials conducted by Janssen Research and Development.